Drugs / Resusix
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03700723 | Dec 2018 → Apr 2020 | blood coagulation disease | Entegrion, Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Resusix | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03700723 ↗ |
| Route | Intravenous | “will be administered intravenously” NCT03700723 ↗ |